Literature DB >> 3621116

Breast cancer in men. Clinical features, hormone receptor status, and response to therapy.

W R Bezwoda, C Hesdorffer, R Dansey, N de Moor, D P Derman, S Browde, M Lange.   

Abstract

Stage, estrogen receptor status, treatment and survival of 29 men with breast cancer attending the Breast Clinic of the Johannesburg Hospital between 1976 and 1985 are reviewed. Most patients had locoregionally advanced disease at presentation. Estrogen receptors (ER) were detected in significant concentration in 15/23 (65%). Local control was achieved in the majority, 19/26 (73%), by either surgery or radiation therapy alone or by combined modality treatment. Fifteen of 23 patients tested (65%) were ER-positive (greater than 10 fmol/mg protein). For patients with metastatic disease hormone receptor status was predictive of response to hormonal manipulation. Tamoxifen was the most acceptable and frequently used form of hormone therapy with 7/12 patients responding. Combination chemotherapy gave a response rate comparable to that seen in women with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3621116     DOI: 10.1002/1097-0142(19870915)60:6<1337::aid-cncr2820600629>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  The management of male breast cancer in Nigerians.

Authors:  F N Ihekwaba
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 2.  Cancer of the male breast: a review.

Authors:  W L Williams; M Powers; L D Wagman
Journal:  J Natl Med Assoc       Date:  1996-07       Impact factor: 1.798

Review 3.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

Review 4.  Carcinoma of the male breast.

Authors:  J F De los Santos; T A Buchholz
Journal:  Curr Treat Options Oncol       Date:  2000-08

Review 5.  Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men.

Authors:  H Stalsberg; D B Thomas; K A Rosenblatt; L M Jimenez; A McTiernan; A Stemhagen; W D Thompson; M G Curnen; W Satariano; D F Austin
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

Review 6.  Lobular carcinoma of the male breast associated with the use of cimetidine.

Authors:  P San Miguel; M Sancho; J L Enriquez; J Fernandez; F Gonzalez-Palacios
Journal:  Virchows Arch       Date:  1997-03       Impact factor: 4.064

7.  Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.

Authors:  A Pich; E Margaria; L Chiusa; G Candelaresi; O Dal Canton
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery.

Authors:  Xin Chai; Mei-Yang Sun; Hong-Yao Jia; Min Wang; Ling Cao; Zhi-Wen Li; Dun-Wei Wang
Journal:  PeerJ       Date:  2019-10-14       Impact factor: 2.984

9.  Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor.

Authors:  D E Gunson; R E Steele; R Y Chau
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

Review 10.  Surgical options for male breast cancer.

Authors:  Ian S Fentiman
Journal:  Breast Cancer Res Treat       Date:  2018-09-05       Impact factor: 4.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.